ClinicalTrials.gg
CompletedNCT03725202SELECT-GCAUpdated Feb 24, 2026Results posted

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

A Phase 3 interventional study of Upadacitinib and Corticosteroid (CS) in Giant Cell Arteritis (GCA), sponsored by AbbVie. Completed at 172 sites in 24 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
429
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Giant Cell Arteritis with a site in United States — 8 open to participants now, 8 under way, 1 of them phase 3. Giant Cell Arteritis · United States.

Enrollment
Largest of 20
429 · median 68
Started
2019
with 2 others
Phase 3
7 of 35
1 open now
Registered
24th of 35
by date
Lead sponsor
1 of 35
AbbVie

Among the 35 studies in Giant Cell Arteritis with a site in United States, this one has the largest enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 3, and was the 24th registered.

Giant Cell Arteritis

149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.

Browse Giant Cell Arteritis studies →

Open to participants now

8 of the 35 studies in Giant Cell Arteritis with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Giant Cell Arteritis with a site in United States, or all of them as a file.
02

Study summary

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured by the proportion of participants in sustained remission at Week 52, and to assess the safety and tolerability of upadacitinib in participants with giant cell arteritis (GCA). The objective of Period 2 is to evaluate the safety and efficacy of continuing versus withdrawing upadacitinib in maintaining remission in participants who achieved sustained remission in Period 1.

03

Conditions studied

  • Giant Cell Arteritis (GCA)

Browse trials for

Keywords

  • Giant Cell Arteritis (GCA)
  • ABT-494
  • Upadacitinib
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of giant cell arteritis (GCA) according to the following criteria:

    • History of erythrocyte sedimentation rate (ESR) >= 50 mm/hour or high sensitivity C-reactive protein (hsCRP)/CRP >=1.0 mg/dL
    • Presence of at least one of the following: Unequivocal cranial symptoms of GCA or Unequivocal symptoms of polymyalgia rheumatica (PMR)
    • Presence of at least one of the following: temporal artery revealing features of GCA or evidence of large vessel vasculitis by angiography or cross-sectional imaging such as ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) or positron emission tomography (PET).
  • Active GCA, either new onset or relapsing, within 8 weeks of Baseline.
  • Participants must have received treatment with >=40 mg prednisone (or equivalent) at any time prior to Baseline and be receiving prednisone (or equivalent) >= 20 mg once daily (QD) at Baseline.
  • Participants must have GCA that, in the opinion of the investigator, is clinically stable to allow the participant to safely initiate the protocol-defined (CS) taper regimen.
  • Females must either be or permanently surgically sterile or, practicing at least 1 specified method of through the study.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus Kinase (JAK) inhibitor.
  • Treatment with an interleukin-6 (IL-6) inhibitor within 4 weeks of study start, or prior treatment with an IL-6 inhibitor and experienced a disease flare during treatment.
  • Use of any of the following systemic treatments within the specified timeframe prior to study start:

    • Anakinra within 1 week of study start.
    • Methotrexate, hydroxychloroquine, cyclosporine, azathioprine, or mycophenolate within 4 weeks of study start.
    • Oral (CS) for conditions other than GCA within 4 week of study start, or intravenous CS within 4 weeks of study start.
    • Greater than or equal to 8 weeks for leflunomide if no elimination procedure was followed, or adhere to an elimination procedure.
    • Cell-depleting agents or alkylating agents including cyclophosphamide within 6 months of study start.
  • Current or past history of infection including herpes zoster or herpes simplex, (HIV), active Tuberculosis, active or chronic recurring infection, active or C.
  • Female who is pregnant, breastfeeding, or considering pregnancy during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
429 participants (actual)

Study arms

  • Placebo comparator
    Placebo + 52-week CS taper

    Participants received placebo tablets for upadacitinib administered orally once daily (QD) for 52 weeks and a 52-week corticosteroid (CS) taper regimen during Period 1.

    Drug: Corticosteroid (CS) · Other: Placebo

  • Experimental
    7.5 mg Upadacitinib + 26-week CS taper

    Participants received 7.5 mg upadacitinib tablets administered orally once daily (QD) for 52 weeks and a 26-week corticosteroid (CS) taper regimen during Period 1.

    Drug: Upadacitinib · Drug: Corticosteroid (CS)

  • Experimental
    15 mg Upadacitinib + 26-week CS taper

    Participants received 15 mg upadacitinib tablets administered orally once daily (QD) for 52 weeks and a 26-week corticosteroid (CS) taper regimen during Period 1.

    Drug: Upadacitinib · Drug: Corticosteroid (CS)

  • Placebo comparator
    Placebo + 52-week CS taper -> Placebo

    Participants who achieved sustained remission for at least 24 weeks prior to the Week 52 visit (at the end of Period 1) OR at remission at the Week 52 visit only who were assigned to placebo tablets for upadacitinib administered orally once daily (QD) in Period 1 continued to receive placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.

    Other: Placebo

  • Experimental
    7.5 mg Upadacitinib + 26-week CS taper -> 7.5 mg Upadacitinib

    Participants received 7.5 mg upadacitinib tablets administered orally once daily (QD) in Period 2.

    Drug: Upadacitinib

  • Experimental
    7.5 mg Upadacitinib + 26-week CS taper -> Placebo

    Participants received placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.

    Other: Placebo

  • Experimental
    15 mg Upadacitinib + 26-week CS taper -> 15 mg Upadacitinib

    Participants received 15 mg upadacitinib tablets administered orally once daily (QD) in Period 2.

    Drug: Upadacitinib

  • Experimental
    15 mg Upadacitinib + 26-week CS taper -> Placebo

    Participants received placebo tablets for upadacitinib administered orally once daily (QD) in Period 2.

    Other: Placebo

Interventions

  • Administered orally once a day

    Also known as: ABT-494, RINVOQ

  • DrugCorticosteroid (CS)

    At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.

  • OtherPlacebo

    Administered orally once a day

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Sustained Remission at Week 52

    Sustained remission is defined as having achieved absence of giant cell arteritis (GCA) signs and symptoms from Week 12 through Week 52, and adherence to the protocol-defined corticosteroid (CS) taper regimen.

    Time frame: From Week 12 to Week 52

Secondary outcomes

  1. Percentage of Participants Achieving Sustained Complete Remission From Week 12 Through Week 52

    Sustained complete remission is defined as having absence of giant cell arteritis (GCA) signs and symptoms from Week 12 through Week 52; normalization of erythrocyte sedimentation rate (ESR); normalization of high sensitivity C-reactive protein (hs-CRP) and adherence to the protocol-defined CS taper regimen.

    Time frame: Week 12 through Week 52

  2. Cumulative Corticosteroid (CS) Exposure Through Week 52

    The cumulative exposure to corticosteroid(s) through Week 52 of the study was documented.

    Time frame: Baseline up to Week 52

  3. Time to First Disease Flare Through Week 52

    Disease flare is defined as an event determined by the investigator to represent recurrence of Giant Cell Arteritis (GCA) signs or symptoms or an erythrocyte sedimentation rate (ESR) measurement \> 30 mm/hr (attributable to GCA) AND requiring an increase in corticosteroid (CS) dose.

    Time frame: Baseline up to Week 52

  4. Percentage of Participants Who Experience at Least 1 Disease Flare Through Week 52

    The percentage of participants who experience at least 1 disease flare was calculated. Disease flare is defined as an event determined by the investigator to represent recurrence of Giant Cell Arteritis (GCA) signs or symptoms or an erythrocyte sedimentation rate (ESR) measurement \> 30 mm/hr (attributable to GCA) AND requiring an increase in corticosteroid (CS) dose.

    Time frame: Baseline up to Week 52

  5. Percentage of Participants in Complete Remission at Week 52

    Complete remission is defined as having achieved absence of Giant Cell Arteritis (GCA) signs and symptoms; normalization of erythrocyte sedimentation rate (ESR) to \< 30 mm/hr-- if ESR ≥30 mm/hr and elevation is not attributable to GCA, this criterion can still be met); normalization of high sensitivity C-reactive protein (hs-CRP) to \< 1 mg/dL; and adherence to the protocol-defined corticosteroid (CS) taper regimen.

    Time frame: At Week 52

  6. Percentage of Participants in Complete Remission at Week 24

    Complete remission is defined as having achieved absence of Giant Cell Arteritis (GCA) signs and symptoms; normalization of erythrocyte sedimentation rate (ESR) to \< 30 mm/hr-- if ESR ≥30 mm/hr and elevation is not attributable to GCA, this criterion can still be met); normalization of high sensitivity C-reactive protein (hs-CRP) to \< 1 mg/dL; and adherence to the protocol-defined corticosteroid (CS) taper regimen.

    Time frame: At Week 24

  7. Change From Baseline in the 36-item Short Form Quality of Life Questionnaire (SF-36) Physical Component Summary (PCS) Score at Week 52

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary (PCS) is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The SF-36 PCS ranges from 0 to 100. A linear algorithm was applied to the calculation of the PCS which has a normative mean value of 50. Higher scores are associated with less disability; a score of 100 is equivalent to no disability and a score of 0 is equivalent to maximum disability. A positive change from the Baseline score indicates improvement.

    Time frame: Baseline, Week 52

  8. Number of Disease Flares Per Participant Through Week 52

    The number of disease flares per participant during Period 1 was documented, and was adjusted by the duration of study participation.

    Time frame: Baseline up to Week 52

  9. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) at Week 52

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue, functional fatigue, emotional fatigue, and social consequences of fatigue. Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing items worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

    Time frame: Baseline, Week 52

  10. Assessment of Treatment Satisfaction Questionnaire for Medication (TSQM) Patient Global Satisfaction Subscale at Week 52

    The Treatment Satisfaction Questionnaire for Medications (TSQM) is a generic ePRO measure of treatment satisfaction, developed to compare treatment satisfaction between medication types and conditions. TSQM comprises of 14 items to assess 4 domains (effectiveness, side effects, convenience, and global satisfaction). The TSQM items are rated on a Likert scale (1 = extremely dissatisfied to 7 = extremely satisfied). Scores for each of the 4 domains range from 0 to 100, with higher scores corresponding to higher satisfaction. A positive change from Baseline indicates improvement.

    Time frame: At Week 52

  11. Rate of Corticosteroid-related Adverse Events Though Week 52

    The rate of corticosteroid-related adverse events was calculated, and was adjusted by duration of study drug exposure.

    Time frame: Baseline up to Week 52

07

Results

Posted Mar 7, 2025

Participant flow

This trial was conducted at 100 sites in 23 countries. Participants were randomized via in a 2:1:1 ratio to receive either upadacitinib 15 mg or 7.5 mg once daily in combination with a predefined 26-week CS taper regimen, or placebo with a predefined 52-week CS taper regimen

Period 1 (Baseline - Week 52)
Participant flow — Period 1 (Baseline - Week 52)
MilestonePlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS TaperPlacebo + 52-week CS Taper -> Placebo7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib7.5 mg Upadacitinib + 26-week CS Taper -> Placebo15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib15 mg Upadacitinib + 26-week CS Taper -> Placebo
Started11210721000000
Randomized11210721000000
Received randomized study drug11210720900000
Completed868517700000
Not completed26223300000
Withdrew: Adverse event13111700000
Withdrew: Withdrew consent561000000
Withdrew: Covid-19 logistical restrictions10000000
Withdrew: Failure to meet continuation criteria20000000
Withdrew: Other, not specified55500000
Withdrew: Did not receive randomized study drug00100000
Period 2 (Week 52 - Week 104)
Participant flow — Period 2 (Week 52 - Week 104)
MilestonePlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS TaperPlacebo + 52-week CS Taper -> Placebo7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib7.5 mg Upadacitinib + 26-week CS Taper -> Placebo15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib15 mg Upadacitinib + 26-week CS Taper -> Placebo
Started0004339149235
Completed0003838128530
Not completed00051275
Withdrew: Adverse event00011242
Withdrew: Withdrew consent00010012
Withdrew: Lost to follow-up00000010
Withdrew: Failure to meet continuation criteria00010000
Withdrew: Other, not specified00020011

Outcome measures

PrimaryPercentage of Participants Achieving Sustained Remission at Week 52

Sustained remission is defined as having achieved absence of giant cell arteritis (GCA) signs and symptoms from Week 12 through Week 52, and adherence to the protocol-defined corticosteroid (CS) taper regimen.

Time frame:
From Week 12 to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Sustained Remission at Week 52
percentage of participantsPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Percentage of Participants Achieving Sustained Remission at Week 5229.0 (20.6 to 37.5)41.1 (31.8 to 50.4)46.4 (39.6 to 53.2)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Cochran-Mantel-Haenszel · p = =0.0019 · Adjusted response rate difference: 17.1 · 95% CI 6.3 to 27.8Response rate difference = 15 mg Upadacitinib - Placebo
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Cochran-Mantel-Haenszel · p = =0.0579 · Adjusted response rate difference: 12.1 · 95% CI -0.4 to 24.6Response rate difference = 7.5 mg Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Sustained Complete Remission From Week 12 Through Week 52

Sustained complete remission is defined as having absence of giant cell arteritis (GCA) signs and symptoms from Week 12 through Week 52; normalization of erythrocyte sedimentation rate (ESR); normalization of high sensitivity C-reactive protein (hs-CRP) and adherence to the protocol-defined CS taper regimen.

Time frame:
Week 12 through Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Sustained Complete Remission From Week 12 Through Week 52
percentage of participantsPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Percentage of Participants Achieving Sustained Complete Remission From Week 12 Through Week 5216.1 (9.3 to 22.9)26.2 (17.8 to 34.5)37.1 (30.5 to 43.7)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 20.7 · 95% CI 11.3 to 30.2Response rate difference = 15 mg Upadacitinib - Placebo
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Cochran-Mantel-Haenszel · p = =0.0699 · Adjusted response rate difference: 9.9 · 95% CI -0.8 to 20.6Response rate difference = 7.5 mg Upadacitinib - Placebo
SecondaryCumulative Corticosteroid (CS) Exposure Through Week 52

The cumulative exposure to corticosteroid(s) through Week 52 of the study was documented.

Time frame:
Baseline up to Week 52
Reported as:
Median · mg
Cumulative Corticosteroid (CS) Exposure Through Week 52
mgPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Cumulative Corticosteroid (CS) Exposure Through Week 522882.0 (2762.00 to 3253.00)1905.0 (1615.00 to 2265.00)1615.0 (1615.00 to 1635.00)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · van Elteren test · p = <0.0001
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · van Elteren test · p = <0.0001
SecondaryTime to First Disease Flare Through Week 52

Disease flare is defined as an event determined by the investigator to represent recurrence of Giant Cell Arteritis (GCA) signs or symptoms or an erythrocyte sedimentation rate (ESR) measurement \> 30 mm/hr (attributable to GCA) AND requiring an increase in corticosteroid (CS) dose.

Time frame:
Baseline up to Week 52
Reported as:
Median · days
Time to First Disease Flare Through Week 52
daysPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Time to First Disease Flare Through Week 52323.0 (249.00 to NA)NA (316.00 to NA)NA (NA to NA)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Log-rank test · p = =0.0025 · Cox proportional hazard: 0.57 · 95% CI 0.399 to 0.826
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Log-rank test · p = =0.1778 · Cox proportional hazard: 0.75 · 95% CI 0.499 to 1.136
SecondaryPercentage of Participants Who Experience at Least 1 Disease Flare Through Week 52

The percentage of participants who experience at least 1 disease flare was calculated. Disease flare is defined as an event determined by the investigator to represent recurrence of Giant Cell Arteritis (GCA) signs or symptoms or an erythrocyte sedimentation rate (ESR) measurement \> 30 mm/hr (attributable to GCA) AND requiring an increase in corticosteroid (CS) dose.

Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Experience at Least 1 Disease Flare Through Week 52
percentage of participantsPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Percentage of Participants Who Experience at Least 1 Disease Flare Through Week 5255.6 (42.9 to 69.2)41.3 (32.2 to 51.7)34.3 (27.4 to 42.4)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Stratified Test for Odds Ratio · p = =0.0014 · Odds ratio (or): 0.47 · 95% CI 0.29 to 0.74This method is described in J Immunother Cancer. 2021 Nov;9(11):e003323. doi: 10.1136/jitc-2021-003323.
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Stratified Test for Odds Ratio · p = =0.0633 · Odds ratio (or): 0.60 · 95% CI 0.35 to 1.03This method is described in J Immunother Cancer. 2021 Nov;9(11):e003323. doi: 10.1136/jitc-2021-003323.
SecondaryPercentage of Participants in Complete Remission at Week 52

Complete remission is defined as having achieved absence of Giant Cell Arteritis (GCA) signs and symptoms; normalization of erythrocyte sedimentation rate (ESR) to \< 30 mm/hr-- if ESR ≥30 mm/hr and elevation is not attributable to GCA, this criterion can still be met); normalization of high sensitivity C-reactive protein (hs-CRP) to \< 1 mg/dL; and adherence to the protocol-defined corticosteroid (CS) taper regimen.

Time frame:
At Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Complete Remission at Week 52
percentage of participantsPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Percentage of Participants in Complete Remission at Week 5219.6 (12.3 to 27.0)43.0 (33.6 to 52.4)50.2 (43.4 to 57.1)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 30.3 · 95% CI 20.4 to 40.2
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 23.5 · 95% CI 11.7 to 35.3
SecondaryPercentage of Participants in Complete Remission at Week 24

Complete remission is defined as having achieved absence of Giant Cell Arteritis (GCA) signs and symptoms; normalization of erythrocyte sedimentation rate (ESR) to \< 30 mm/hr-- if ESR ≥30 mm/hr and elevation is not attributable to GCA, this criterion can still be met); normalization of high sensitivity C-reactive protein (hs-CRP) to \< 1 mg/dL; and adherence to the protocol-defined corticosteroid (CS) taper regimen.

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants in Complete Remission at Week 24
percentage of participantsPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Percentage of Participants in Complete Remission at Week 2436.1 (27.2 to 45.1)39.3 (30.0 to 48.5)57.2 (50.5 to 64.0)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Cochran-Mantel-Haenszel · p = =0.0002 · Adjusted response rate difference: 20.8 · 95% CI 9.7 to 31.9
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Cochran-Mantel-Haenszel · p = =0.6276 · Adjusted response rate difference: 3.2 · 95% CI -9.6 to 16.0
SecondaryChange From Baseline in the 36-item Short Form Quality of Life Questionnaire (SF-36) Physical Component Summary (PCS) Score at Week 52

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary (PCS) is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The SF-36 PCS ranges from 0 to 100. A linear algorithm was applied to the calculation of the PCS which has a normative mean value of 50. Higher scores are associated with less disability; a score of 100 is equivalent to no disability and a score of 0 is equivalent to maximum disability. A positive change from the Baseline score indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in the 36-item Short Form Quality of Life Questionnaire (SF-36) Physical Component Summary (PCS) Score at Week 52
units on a scalePlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Change From Baseline in the 36-item Short Form Quality of Life Questionnaire (SF-36) Physical Component Summary (PCS) Score at Week 52-1.2892 (-3.3093 to 0.7309)1.3202 (-0.6553 to 3.2957)2.4634 (1.1707 to 3.7561)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Mixed-Effect Model Repeat Measurement · p = =0.0019 · Ls mean difference: 3.7526 · 95% CI 1.3932 to 6.1119Difference = 15 mg Upadacitinib - Placebo
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Mixed-Effect Model Repeat Measurement · p = =0.0670 · Ls mean difference: 2.6094 · 95% CI -0.1841 to 5.4028Difference = 7.5 mg Upadacitinib - Placebo
SecondaryNumber of Disease Flares Per Participant Through Week 52

The number of disease flares per participant during Period 1 was documented, and was adjusted by the duration of study participation.

Time frame:
Baseline up to Week 52
Reported as:
Mean · Disease Flare per Participant per Year
Number of Disease Flares Per Participant Through Week 52
Disease Flare per Participant per YearPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Number of Disease Flares Per Participant Through Week 520.7 (0.5 to 0.9)0.6 (0.4 to 0.7)0.4 (0.3 to 0.5)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Poisson regression model · p = 0.0010 · Rate ratio: 0.6 · 95% CI 0.4 to 0.8
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Poisson regression model · p = =0.2722 · Rate ratio: 0.8 · 95% CI 0.6 to 1.2
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) at Week 52

The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue, functional fatigue, emotional fatigue, and social consequences of fatigue. Participants respond to the questions on a scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue score is computed by summing the item scores, after reversing items worded in the negative direction. The FACIT-Fatigue score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) at Week 52
units on a scalePlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) at Week 52-2.4 (-4.71 to -0.07)1.1 (-1.17 to 3.37)1.7 (0.18 to 3.14)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Mixed-Effect Model Repeat Measurement · p = =0.0036 · Ls mean difference: 4.0 · 95% CI 1.33 to 6.76Difference = 15 mg Upadacitinib -Placebo
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Mixed-Effect Model Repeat Measurement · p = =0.0338 · Ls mean difference: 3.5 · 95% CI 0.27 to 6.70Difference = 7.5 mg Upadacitinib -Placebo
SecondaryAssessment of Treatment Satisfaction Questionnaire for Medication (TSQM) Patient Global Satisfaction Subscale at Week 52

The Treatment Satisfaction Questionnaire for Medications (TSQM) is a generic ePRO measure of treatment satisfaction, developed to compare treatment satisfaction between medication types and conditions. TSQM comprises of 14 items to assess 4 domains (effectiveness, side effects, convenience, and global satisfaction). The TSQM items are rated on a Likert scale (1 = extremely dissatisfied to 7 = extremely satisfied). Scores for each of the 4 domains range from 0 to 100, with higher scores corresponding to higher satisfaction. A positive change from Baseline indicates improvement.

Time frame:
At Week 52
Reported as:
Least squares mean · units on a scale
Assessment of Treatment Satisfaction Questionnaire for Medication (TSQM) Patient Global Satisfaction Subscale at Week 52
units on a scalePlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Assessment of Treatment Satisfaction Questionnaire for Medication (TSQM) Patient Global Satisfaction Subscale at Week 5268.8428 (63.8310 to 73.8547)74.2644 (69.4483 to 79.0805)71.5753 (68.3375 to 74.8131)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Mixed-Effect Model Repeat Measurement · p = =0.3573 · Ls mean difference: 2.7325 · 95% CI -3.1020 to 8.5670Difference = 15 mg Upadacitinib -Placebo
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Mixed-Effect Model Repeat Measurement · p = =0.1203 · Ls mean difference: 5.4216 · 95% CI -1.4269 to 12.2701Difference = 7.5 mg Upadacitinib -Placebo
SecondaryRate of Corticosteroid-related Adverse Events Though Week 52

The rate of corticosteroid-related adverse events was calculated, and was adjusted by duration of study drug exposure.

Time frame:
Baseline up to Week 52
Reported as:
Mean · CS-related AE per participant per year
Rate of Corticosteroid-related Adverse Events Though Week 52
CS-related AE per participant per yearPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS Taper
Rate of Corticosteroid-related Adverse Events Though Week 521.7 (1.3 to 2.3)1.7 (1.2 to 2.2)2.0 (1.7 to 2.4)
Statistical analysis
  • Placebo + 52-week CS Taper vs 15 mg Upadacitinib + 26-week CS Taper · Poisson regression model · p = =0.4371 · Rate ratio: 1.1 · 95% CI 0.8 to 1.6
  • Placebo + 52-week CS Taper vs 7.5 mg Upadacitinib + 26-week CS Taper · Poisson regression model · p = =0.7749 · Rate ratio: 0.9 · 95% CI 0.6 to 1.4

Adverse events

Collected over All-cause mortality and adverse events were collected from the time informed consent was signed through the end of the study. Median time on follow-up was 378 days for Pbo (Period 1); 377 days for Upa 7.5 mg (Period 1); 378 days for Upa 15 mg (Period 1); 364 days for Pbo -> Pbo (Period 2); 364 days for 7.5 mg Upa -> 7.5 mg Upa (Period 2); 363.5 days for 7.5 mg Upa -> Pbo (Period 2); 364 days for 15 mg Upa -> 15 mg Upa (Period 2); and 364 days for 15 mg Upa -> Pbo (Period 2).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + 52-week CS Taper2/112 (1.8%)24/112 (21.4%)90/112 (80.4%)
7.5 mg Upadacitinib + 26-week CS Taper0/107 (0%)14/107 (13.1%)88/107 (82.2%)
15 mg Upadacitinib + 26-week CS Taper3/210 (1.4%)50/210 (23.8%)174/210 (82.9%)
Placebo + 52-week CS Taper -> Placebo0/43 (0%)9/43 (20.9%)34/43 (79.1%)
7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib0/39 (0%)6/39 (15.4%)27/39 (69.2%)
7.5 mg Upadacitinib + 26-week CS Taper -> Placebo0/14 (0%)1/14 (7.1%)12/14 (85.7%)
15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib0/92 (0%)14/92 (15.2%)67/92 (72.8%)
15 mg Upadacitinib + 26-week CS Taper -> Placebo0/35 (0%)5/35 (14.3%)31/35 (88.6%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS TaperPlacebo + 52-week CS Taper -> Placebo7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib7.5 mg Upadacitinib + 26-week CS Taper -> Placebo15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib15 mg Upadacitinib + 26-week CS Taper -> Placebo
ASTHMARespiratory, thoracic and mediastinal disorders0/1120/1070/2100/430/391/140/920/35
ATRIAL FIBRILLATIONCardiac disorders0/1120/1071/2100/430/390/142/922/35
PNEUMONIAInfections and infestations5/1123/1070/2101/430/390/142/920/35
LARGE INTESTINE POLYPGastrointestinal disorders0/1120/1070/2100/430/390/140/921/35
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders1/1120/1070/2100/430/390/140/921/35
OSTEOARTHRITISMusculoskeletal and connective tissue disorders1/1120/1072/2101/430/390/142/921/35
DIVERTICULITISInfections and infestations0/1120/1070/2100/431/390/140/920/35
LUMBAR SPINAL STENOSISMusculoskeletal and connective tissue disorders0/1121/1070/2101/431/390/140/920/35
LUNG ADENOCARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1120/1070/2100/431/390/140/920/35
PAPILLARY THYROID CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1120/1070/2100/431/390/140/920/35
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPlacebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS TaperPlacebo + 52-week CS Taper -> Placebo7.5 mg Upadacitinib + 26-week CS Taper -> 7.5 mg Upadacitinib7.5 mg Upadacitinib + 26-week CS Taper -> Placebo15 mg Upadacitinib + 26-week CS Taper -> 15 mg Upadacitinib15 mg Upadacitinib + 26-week CS Taper -> Placebo
GIANT CELL ARTERITISVascular disorders34/11227/10745/2109/432/395/149/9214/35
ARTHRALGIAMusculoskeletal and connective tissue disorders15/1127/10728/21010/431/391/1412/923/35
COVID-19Infections and infestations12/11212/10727/2107/437/393/1417/926/35
HEADACHENervous system disorders13/11216/10733/2102/433/390/1414/921/35
URINARY TRACT INFECTIONInfections and infestations17/11215/10721/2101/433/391/144/921/35
HYPERTENSIONVascular disorders13/11216/10728/2102/432/390/146/925/35
RESPIRATORY TRACT INFECTIONInfections and infestations0/1121/1073/2101/432/392/142/921/35
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations8/1128/10711/2102/430/392/146/921/35
BACK PAINMusculoskeletal and connective tissue disorders14/1126/10725/2101/430/392/145/923/35
NASOPHARYNGITISInfections and infestations14/1126/10718/2104/434/390/148/923/35

Baseline characteristics

Full analysis set in Period 1 (FAS1): all randomized participants who received at least 1 dose of study drug in Period 1

Age, Continuous
Age, Continuous(years)Placebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS TaperTotal
Mean71.6 ± 7.3371.1 ± 7.5570.8 ± 7.3171.1 ± 7.37
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS TaperTotal
Female7780156313
Male352753115
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS TaperTotal
Hispanic or Latino52613
Not Hispanic or Latino107105203415
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + 52-week CS Taper7.5 mg Upadacitinib + 26-week CS Taper15 mg Upadacitinib + 26-week CS TaperTotal
American Indian or Alaska Native0000
Asian661022
Native Hawaiian or Other Pacific Islander0101
Black or African American2103
White10399199401
More than one race1001
Unknown or Not Reported0000
08

Study locations

172 sites
  • Rheum Assoc of North Alabama /ID# 168668
    Huntsville, Alabama 35801, United States
  • Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 204702
    Glendale, Arizona 85306-9802, United States
  • VA Long Beach Healthcare System /ID# 203833
    Long Beach, California 90822-5201, United States
  • Robin K. Dore MD, Inc /ID# 201950
    Tustin, California 92780, United States
  • Denver Arthritis Clinic /ID# 171552
    Denver, Colorado 80230, United States
  • Duplicate_Western Connecticut Health Network- Germantown Rd /ID# 205071
    Danbury, Connecticut 06810-5038, United States
  • Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 169040
    Boca Raton, Florida 33486, United States
  • Lakes Research, LLC /ID# 210442
    Miami, Florida 33014, United States
  • Ctr Arthritis & Rheumatic Dise /ID# 168667
    Miami, Florida 33173, United States
  • Medallion Clinical Research Institute, LLC /ID# 168666
    Naples, Florida 34102, United States
  • Omega Research Group /ID# 201903
    Orlando, Florida 32808, United States
  • IRIS Research and Development, LLC /ID# 169406
    Plantation, Florida 33324, United States
  • Clinical Research of West Florida - Tampa /ID# 201899
    Tampa, Florida 33606-1246, United States
  • Clinical Research of West Florida, Inc /ID# 201901
    Tampa, Florida 33606-1246, United States
  • Duplicate_University of South Florida /ID# 207077
    Tampa, Florida 33612-2201, United States
  • Lovelace Scientific Resources /ID# 169041
    Venice, Florida 34292, United States
  • Arthritis and Rheumatology /ID# 170295
    Atlanta, Georgia 30342, United States
  • Institute of Arthritis Research /ID# 168490
    Idaho Falls, Idaho 83404, United States
  • Duplicate_Rush University Medical Center /ID# 224581
    Chicago, Illinois 60612, United States
  • Ochsner Clinic Foundation /ID# 200723
    Baton Rouge, Louisiana 70836-6455, United States
  • The Arthritis & Diabetes Clinic, Inc. /ID# 171199
    Monroe, Louisiana 71203, United States
  • Ochsner Clinic Foundation-New Orleans /ID# 171200
    New Orleans, Louisiana 70121, United States
  • Louisiana State Univ HSC /ID# 202646
    Shreveport, Louisiana 71130, United States
  • Rheumatology Associates PA - Portland /ID# 225011
    Portland, Maine 04102-2643, United States
  • The Center for Rheumatology and Bone Research /ID# 168652
    Wheaton, Maryland 20902, United States
  • University of Michigan Hospitals /ID# 168645
    Ann Arbor, Michigan 48109-5008, United States
  • Wayne State University Health Center /ID# 212755
    Detroit, Michigan 48201-2153, United States
  • Henry Ford Medical Center - New Center One /ID# 207456
    Detroit, Michigan 48202-3046, United States
  • Duplicate_AA Medical Research Center - Grand Blanc /ID# 201854
    Grand Blanc, Michigan 48439, United States
  • Duplicate_West Michigan Rheumatology /ID# 168647
    Grand Rapids, Michigan 49546, United States
  • Clinvest Research LLC /ID# 208182
    Springfield, Missouri 65807, United States
  • Physician Research Collaboration, LLC /ID# 168610
    Lincoln, Nebraska 68516, United States
  • University Clinical Research Center /ID# 202504
    Somerset, New Jersey 08873-3448, United States
  • University of Rochester Medical Center /ID# 213527
    Rochester, New York 14642, United States
  • Marietta Memorial Hospital /ID# 210834
    Marietta, Ohio 45750-1635, United States
  • STAT Research, Inc. /ID# 200436
    Vandalia, Ohio 45377-9464, United States
  • University of Pennsylvania /ID# 168655
    Philadelphia, Pennsylvania 19104-5502, United States
  • Piedmont Arthritis Clinic, PA /ID# 212431
    Greenville, South Carolina 29601, United States
  • Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 212761
    Summerville, South Carolina 29486-7887, United States
  • West Tennessee Research Institute /ID# 209256
    Jackson, Tennessee 38305, United States
  • Arthritis Associates of Kingsport /ID# 212756
    Kingsport, Tennessee 37660, United States
  • Allen Arthritis /ID# 225527
    Allen, Texas 75013, United States
  • Tekton Research, L.L.C /ID# 201801
    Austin, Texas 78745, United States
  • Precision Comprehensive Clinical Research Solutions /ID# 201798
    Colleyville, Texas 76034, United States
  • West Texas Clinical Research /ID# 204834
    Lubbock, Texas 79424, United States
  • Arthritis and Rheumatology Institute, PLLC /ID# 214612
    Plano, Texas 75093-6419, United States
  • Baylor Scott & White Center for Diagnostic Medicine /ID# 213529
    Temple, Texas 76508, United States
  • University of Vermont Medical Center /ID# 211179
    Burlington, Vermont 05401-1473, United States
  • Carilion Clinic /ID# 212928
    Roanoke, Virginia 24016, United States
  • Kadlec Clinic Rheumatology /ID# 201618
    Kennewick, Washington 99336, United States
  • University of Washington /ID# 201619
    Seattle, Washington 98109, United States
  • Aurora Rheumatology and Immunotherapy Center /ID# 201853
    Franklin, Wisconsin 53132, United States
  • Froedtert Memorial Lutheran Hospital /ID# 224557
    Milwaukee, Wisconsin 53226-3522, United States
  • Emeritus Research Sydney /ID# 201937
    Botany, New South Wales 2019, Australia
  • Prince of Wales Hospital /ID# 210995
    Randwick, New South Wales 2031, Australia
  • Griffith University /ID# 223829
    Southport, Queensland 4222, Australia
  • The Queen Elizabeth Hospital /ID# 201939
    Woodville South, South Australia 5011, Australia
  • Emeritus Research /ID# 201938
    Camberwell, Victoria 3124, Australia
  • Fiona Stanley Hospital /ID# 201941
    Murdoch, Western Australia 6150, Australia
  • Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 201781
    Vienna, State of Vienna 1100, Austria
  • Medizinische Universitaet Innsbruck /ID# 201786
    Innsbruck, Tyrol 6020, Austria
  • Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 224334
    Yvoir, Namur 5530, Belgium
  • UZ Gent /ID# 202778
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Universitair Ziekenhuis Leuven /ID# 202779
    Leuven, Vlaams-Brabant 3000, Belgium
  • Duplicate_University of Alberta Hospital - Division of Hematology /ID# 208629
    Edmonton, Alberta T6G 2B7, Canada
  • St. Joseph's Healthcare /ID# 204160
    Hamilton, Ontario L8N 4A6, Canada
  • CISSSBSL -Hopital regional de Rimouski /ID# 224266
    Rimouski, Quebec G5L 5T1, Canada
  • Centre de Recherche Musculo-Squelettique /ID# 201224
    Trois-Rivières, Quebec G8Z 1Y2, Canada
  • Rheumatology Associates /ID# 201843
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Fakultni nemocnice Olomouc /ID# 202041
    Olomouc, 779 00, Czechia
  • Axon Clinical, s.r.o. /ID# 202468
    Prague, 140 00, Czechia
  • Medical Plus, s.r.o. /ID# 200865
    Uherské Hradiště, 686 01, Czechia
  • Aarhus University Hospital /ID# 171177
    Aarhus C, Central Jutland 8000, Denmark
  • Sydvestjysk Sygehus /ID# 200216
    Esbjerg, Region Syddanmark 6700, Denmark
  • Hopital Saint Joseph /ID# 171540
    Marseille, Bouches-du-Rhone 13008, France
  • CHU Dijon /ID# 225277
    Dijon, Cote-d Or 21000, France
  • Hopital de la Cavale Blanche /ID# 171549
    Brest, Finistere 29200, France
  • CHU Toulouse - Hopital Purpan /ID# 171547
    Toulouse, Haute-Garonne 31059, France
  • CHRU Lille - Hopital Claude Huriez /ID# 171543
    Lille, Nord 59037, France
  • Hopitaux Universitaires Paris Centre-Hopital Cochin /ID# 171545
    Paris, Paris 75679, France
  • CHU de Nantes, Hotel Dieu -HME /ID# 171544
    Nantes, Pays de la Loire Region 44000, France
  • HCL - Hopital de la Croix-Rousse /ID# 211184
    Lyon, Rhone 69004, France
  • CHU de CAEN - Hopital de la Cote de Nacre /ID# 171539
    Caen, 14033, France
  • CHRU Tours - Hopital Trousseau /ID# 245232
    Chambray-lès-Tours, 37170, France
  • Hopital Pitie Salpetriere /ID# 171542
    Paris, Île-de-France Region 75013, France
  • Medius Klinik Kirchheim /ID# 200637
    Kirchheim unter Teck, Baden-Wurttemberg 73230, Germany
  • Universitaetsklinikum Tuebingen /ID# 223854
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Universitaetsklinikum Wuerzburg /ID# 213340
    Würzburg, Bavaria 97080, Germany
  • Immanuel Krankenhaus Berlin /ID# 223855
    Buch, 13125, Germany
  • Medizinische Versorgungszentren Burghausen Altoetting /ID# 208773
    Burghausen, 84489, Germany
  • Medizinische Hochschule Hannover /ID# 200632
    Hanover, 30625, Germany
  • General Hospital of Athens Gennimatas /ID# 210129
    Athens, Attica 11527, Greece
  • General Hospital of Athens Ippokratio /ID# 202181
    Athens, Attica 11527, Greece
  • 424 General MILITARY Hospital /ID# 210973
    Efkarpia (Thessalonikis), Thessaloniki 56429, Greece
  • Debreceni Egyetem-Klinikai Kozpont /ID# 201526
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 204018
    Budapest, 1023, Hungary
  • Orszagos Reumatologiai es Fizioterapias Intezet /ID# 211454
    Budapest, 1023, Hungary
  • Del-Budai Centrumkorhaz Szent Imre Egyetemi Oktatokorhaz /ID# 201838
    Budapest, 1115, Hungary
  • Bnai Zion Medical Center /ID# 240733
    Haifa, H_efa 3339419, Israel
  • The Lady Davis Carmel Medical Center /ID# 240731
    Haifa, H_efa 34362, Israel

Showing the first 100 of 172 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, Keen HI, Ishii T, Khalidi N, Dejaco C, Cid MC, Hellmich B, Liu M, Zhao W, Lagunes I, Romero AB, Wung PK, Merkel PA; SELECT-GCA Study Group. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med. 2025 May 29;392(20):2013-2024. doi: 10.1056/NEJMoa2413449. Epub 2025 Apr 2. PubMed 40174237 ↗
  • Loricera J, Tofade T, Prieto-Pena D, Romero-Yuste S, de Miguel E, Riveros-Frutos A, Ferraz-Amaro I, Labrador E, Maiz O, Becerra E, Narvaez J, Galindez-Agirregoikoa E, Gonzalez-Fernandez I, Urruticoechea-Arana A, Ramos-Calvo A, Lopez-Gutierrez F, Castaneda S, Unizony S, Blanco R. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature. Arthritis Res Ther. 2024 Jun 5;26(1):116. doi: 10.1186/s13075-024-03314-9. PubMed 38840219 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Feb 2024, 60 months.

Results were first posted in Mar 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2018
First posted
Oct 30, 2018
StartActual
Jan 24, 2019
Primary completionActual
Feb 6, 2024
CompletionActual
Mar 11, 2025
Results first posted
Mar 7, 2025
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03725202
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 30, 2018
Start date
Jan 24, 2019
Primary completion
Feb 6, 2024
Completion
Mar 11, 2025
Results posted
Mar 7, 2025
Last update
Feb 24, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion